Mid-America Apartment Communities, Inc. is a real estate investment trust, which engages in the operation, acquisition, and development of apartment communities. It operates through the Same Store and Non-Same Store segments. The Same Store Communities segment represents those apartment communities that have been owned and stabilized for at least 12 months as of the first day of the calendar year. The Non-Same Store segment includes recent acquisitions, communities in development or lease-up. The company was founded in 1994 and is headquartered in Germantown, TN.
Analyst recommendations
Mid-America Apartment Communities, Inc. is a real estate investment trust, which engages in the operation, acquisition, and development of apartment communities. It operates through the Same Store and Non-Same Store segments. The Same Store Communities segment represents those apartment communities that have been owned and stabilized for at least 12 months as of the first day of the calendar year. The Non-Same Store segment includes recent acquisitions, communities in development or lease-up. The company was founded in 1994 and is headquartered in Germantown, TN.
Like its REIT peers, MAA beat expectations in the first quarter. However, that overperformance didn’t change its outlook for the rest of 2025. “Despite...
Mid-America Apartment Communities (NYSE:MAA – Free Report) had its target price raised by Barclays from $160.00 to $172.00 in a report released on Friday,Benzinga reports. Wells Fargo & Company ...
We're also moving forward to complete and submit a marketing authorization application or MAA to the European Medicines Authority for narsoplimab in TATMA. We're targeting to complete that submission ...
The FCA issued a consultation paper on 7 May 2025 seeking feedback on regulatory proposals to simplify advice rules and affordability assessments for mortgages, making it easier, faster and ...
As David mentioned, our BLA was accepted under priority review by the FDA and the MAA was validated by the EMA in Europe. Turning first to the FDA. We were gratified that our BLA for apitegromab ...